Peptides Just Got a Step Closer to Legal Compounding: Here's What That Actually Means

On July 23 and 24, the FDA's Pharmacy Compounding Advisory Committee (PCAC) met to review seven peptides for possible inclusion on the Section 503A Bulks List, and by the end of the two days, it voted to recommend six of them.

The peptides discussed included:

• BPC-157
• KPV
• TB-500
• MOTS-c
• Emideltide (DSIP)
• Semax
• Epitalon

These substances have attracted attention for years, particularly in wellness and regenerative medicine, yet there has never been a clear federal pathway allowing them to be legally compounded. Although it’s important to note that a PCAC vote is only a non-binding recommendation to the FDA, the FDA isn't obligated to follow it, and a favorable vote doesn't constitute drug approval or any other FDA authorization of these peptides, it is a huge move for the burgeoning sterile compounding industry.

What Happened During the PCAC Meetings

This meeting followed another notable development earlier this year. In April, the FDA removed these same peptides from its Category 2 list after the companies that had nominated them withdrew their requests. That change cleared the way for the advisory committee to evaluate whether the substances belong on the 503A Bulks List.

Ahead of the July meeting, agency staff had reviewed each substance under the FDA's four-part balancing test, which covers physical and chemical characterization, historical compounding use, evidence of effectiveness, and safety. They concluded that none of the seven met the bar for inclusion.

However, the committee voted question by question over the two days at the end of July and BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon all received favorable recommendations. Emideltide was the only peptide rejected.

The committee's decision to favorably recommend six of them anyway means the panel moved further than the agency's own reviewers were willing to go.

This Is Not FDA Approval

A PCAC recommendation is not the same thing as FDA drug approval, even if the PCAC recommendation is taken to add these peptides Section 503A Bulks List.

When a bulk drug substance is added to the list, it becomes eligible for use by state-licensed compounding pharmacies and physicians preparing medications for individual patients with valid prescriptions. It's not a determination that the substance is safe or effective on its own.

It's also worth remembering that the advisory committee doesn't have the final say. Its role is to provide advice and recommendations to the FDA on regulatory issues. The agency takes those recommendations seriously, but isn't required to follow them, and there's no set timeline for a final decision.

If the FDA does move forward, it still has to complete formal notice-and-comment rulemaking before any of these substances are actually added to the list.

What This Means in Practice

For anyone using or working with these peptides, the practical upshot is that nothing has changed yet, but momentum for peptides has.

A favorable committee vote is a meaningful signal: it suggests a legitimate regulatory pathway is taking shape for substances that have mostly existed in a gray market until now, sold online or through wellness clinics without a clear legal channel for compounding pharmacies to prepare them.

For compounding pharmacies, telehealth companies, and medical practices building marketing or educational materials, the distinction matters mostly because "eligible for compounding" and "FDA approved" mean different things and mixing them up can have severe regulatory consequences.

What Comes Next

The FDA will now decide whether to accept the committee's recommendations for the 6 approved peptides and whether to move forward with the rulemaking needed to officially add them to the Section 503A Bulks List. There's no deadline for that decision, and the rulemaking process itself is expected to run into 2027 at the earliest. A second advisory committee meeting is already planned before the end of February 2027 to evaluate five additional peptides.

One theme that came up repeatedly during this review was the importance of evidence. Public comments backed by clinical data and documented patient need seemed to carry the most weight.

Final Thoughts

This was a real step forward for the compounding industry, and a more consequential one than many expected given how strongly FDA scientists have recommended against peptides.

Stay Ahead of Regulatory Developments With LighthouseAI

As the FDA continues to evaluate these peptides and the rulemaking process moves forward, the regulatory landscape for compounding pharmacies, telehealth companies, and medical practices will continue to evolve.

Understanding your state licensing obligations and staying current on changing requirements will be critical for organizations operating in this space.

LighthouseAI specializes in helping pharmaceutical supply chain companies navigate the complexity of state licensing and regulatory requirements, including those related to peptide manufacturing and distribution.

Have questions about your licensing obligations? Contact us today.